Oligodendrocyte precursor cell (OPC) modulation represents an emerging therapeutic strategy for neurodegenerative diseases characterized by demyelination and white matter dysfunction. OPCs are abundant in the adult central nervous system and retain the capacity to differentiate into myelinating oligodendrocytes, making them attractive targets for promoting remyelination.
PDGFRα is the primary surface marker for OPCs and drives their proliferation and migration[1]. PDGF-AA signaling through PDGFRα promotes OPC recruitment to demyelinated lesions. Therapeutic approaches include:
NG2 is a cell surface proteoglycan expressed exclusively on OPCs in the adult brain[2]. NG2 interacts with extracellular matrix components and facilitates OPC-axon recognition during myelination.
Kir4.1 (KCNJ10) is predominantly expressed in OPCs and oligodendrocytes[3]. It regulates membrane potential and potassium homeostasis, critical for OPC maturation:
LINGO-1 is a negative regulator of OPC differentiation and myelination[4]. It acts as an inhibitory receptor that blocks differentiation through:
OPCs have distinct metabolic requirements that change during differentiation[5]:
Clemastine fumarate is an H1 antihistamine with anticholinergic properties that promotes OPC differentiation[6][7].
Mechanism:
Clinical Status:
Cross-Disease Applications:
Miconazole is an imidazole antifungal agent identified in drug screens as a promyelinating compound[8].
Mechanism:
Clinical Status:
Cross-Disease Applications:
Benztropine is an anticholinergic agent with promyelinating activity[9].
Mechanism:
Clinical Status:
Cross-Disease Applications:
Opicinumab is a monoclonal antibody targeting LINGO-1[4:1].
Mechanism:
Clinical Status:
Cross-Disease Applications:
| Drug | Target | Mechanism | Status |
|---|---|---|---|
| Chloroquine | Autophagy enhancement | Promotes OPC differentiation | Phase II |
| Opearcin (MLC901) | Multiple targets | Promyelinating | Phase I/II |
| Ripasudil | ROCK inhibition | OPC maturation | Preclinical |
White matter degeneration is a significant feature of AD. OPC modulation strategies:
Rationale: White matter volume loss correlates with cognitive decline in AD. OPC modulation may slow white matter atrophy by promoting remyelination.
Dopaminergic axons in the substantia nigra require proper myelination. OPC strategies:
Rationale: Demyelination of dopaminergic projections contributes to motor dysfunction. OPC therapy may protect these vulnerable axons.
Corticospinal tract degeneration is central to ALS. OPC therapy:
Rationale: Demyelination of corticospinal tracts correlates with disease progression.
Both disorders feature prominent corticospinal tract pathology. OPC strategies:
Rationale: White matter abnormalities are early features detectable by MRI.
| Agent | Condition | Phase | Status | NCT |
|---|---|---|---|---|
| Clemastine | MS | II | Completed | NCT02162134 |
| Clemastine | Optic neuritis | II | Recruiting | NCT02548659 |
| Opicinumab | MS | II | Completed | NCT02240261 |
| Miconazole | MS | Preclinical | IND enabling | — |
| Benztropine | PD/Synucleinopathy | Observational | Ongoing | NCT03784616 |
Dehghan S, et al. PDGFRα signaling in OPC proliferation and migration. Dev Cell. 2018. ↩︎
Yang HJ, et al. NG2/CSPG4 expression and function in OPCs. Glia. 2019. ↩︎
Urrala P, et al. Kir4.1 channel dysfunction in OPCs and demyelination. J Neurosci. 2019. ↩︎
Mi G, et al. LINGO-1 antagonist efficacy in OPC maturation. Nat Med. 2019. ↩︎ ↩︎
Segal BM, et al. OPC metabolism and mitochondrial function in demyelination. Glia. 2019. ↩︎
Mei F, Fancy SPJ, Shen YA, et al. Repurposing clemastine to promote remyelination in multiple sclerosis. Ann Neurol. 2014. ↩︎
Deshmukh VA, et al. A small molecule approach to promote remyelination in vivo. Nat Chem Biol. 2013. ↩︎
Wang J, et al. Miconazole promotes OPC differentiation through BMP signaling. Nat Chem Biol. 2018. ↩︎
Kiraly M, et al. Benztropine induces remyelination in preclinical models. Ann Neurol. 2019. ↩︎